The benefits of Robotic Magnetic Navigation (RMN) have been demonstrated extensively in the real world experience of hundreds of physicians at over one hundred leading hospitals globally. They have also been demonstrated with scientific rigor in hundreds of peer-reviewed publications. We encourage you to review the clinical data detailing the reduced safety risks and improved care patients receive when being treated with RMN.
Differentiation in the competitive healthcare industry is critical to attracting patients, recruiting medical talent, developing robust referral networks and negotiating with payors. Adopting cutting-edge robotic technology provides that competitive differentiation while advancing clinical care, reducing occupational risk, and fueling practice growth.
- Lip GYH, Kakar P, Watson T. Atrial fibrillation—the growing epidemic. Heart. 2007;93(5):542–543.
- Turagam MK, Atkins D, Tung R, Mansour M, Ruskin J, Cheng J, Di Biase L, Natale A, Lakkireddy D. A meta-analysis of manual versus remote magnetic navigation for ventricular tachycardia ablation. J Interv Card Electrophysiol. 2017;49(3):227-235.
- Klein LW, Tra Y, Garratt KN, Powell W, Lopez-Cruz G, Chambers C, et al. Occupational health hazards of interventional cardiologists in the current decade: Results of the 2014 SCAI membership survey. Catheter Cardiovasc Interv. 2015;86(5):913-24.
Stereotaxis Intended Use Statements, United States Labeling:
The Niobe™ ES system is intended to navigate compatible magnetic devices through tissue to designated target sites in the right and left heart, coronary vasculature, neurovasculature, and peripheral vasculature by orienting the device tip in a desired direction. The Stereotaxis Cardiodrive™ automated catheter advancement system (CAS) is intended for automatically advancing and retracting only compatible magnetic electrophysiology (EP) mapping and ablation catheters inside the patient’s heart when used in conjunction with a Stereotaxis magnetic navigation system. The Cardiodrive™ system is not intended to advance the EP mapping and ablation catheters through the coronary vasculature or the coronary sinus.
Consult the associated product labeling for the Indications for Use and instructions of other devices used in conjunction with Stereotaxis products.
Niobe™ and Cardiodrive™ are trademarks of Stereotaxis, Inc. registered in the United States, European Community, and Japan.